Vir Biotechnology (VIR) news
Recent news
Vir Biotechnology Q2 EPS USD 0.47 (corrects amount)
Vir Biotechnology, Inc. (Nasdaq: VIR) reported a net loss of $111.0 million, or $0.80 per share, for the second quarter of 2025, compared to net loss of $138.4 million , or $1.02 per share, for the same period in 2024. The company ended the quarter with $892.1 million in cash, cash equivalents, and…
AInvest Wire · Aug 5, 2026Vir Biotechnology falls 4% as CEO to exit
Vir Biotechnology (VIR) shares declined approximately 4% in early trading on July 24, 2026, following the announcement that its chief executive officer, George Painter, will be exiting the company [1]. Painter, who has led the firm since 2017, will step down in the coming months, with the board…
AInvest Wire · Jul 24, 2026Vir Biotechnology falls 4% as CFO to exit
AInvest Wire · Jul 24, 2026Vir Biotech names Brent Sabatini interim principal fine officer
Vir Biotech has announced that Brent Sabatini has been appointed as interim principal financial officer, effective immediately. This decision follows recent leadership changes within the company’s finance department. Sabatini brings extensive financial expertise to the role, having previously held…
AInvest Wire · Jul 24, 2026Vir Biotech CFO U Byrne to leave, pursue another opportunity
AInvest Wire · Jul 24, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.